Tag: madeinIndia

  • US report suggests child deaths in Gambia linked to made-in-India cough syrups

    US report suggests child deaths in Gambia linked to made-in-India cough syrups

    [ad_1]

    New Delhi: A joint probe by the Centers for Disease Control and Prevention (CDC) of the US and the Gambian health authorities have suggested a strong link between the death of many children in Gambia and the consumption of made-in-India cough syrups that were allegedly contaminated.

    In October, the World Health Organization (WHO) had issued an alert stating that the four cough syrups being supplied to Gambia by the India-based Maiden Pharmaceuticals Ltd were of substandard quality and claimed that they were linked to the death of many children in Gambia.

    A CDC report released on Friday stated, “This investigation strongly suggests that medications contaminated with Diethylene Glycol [DEG] or Ethylene Glycol [EG] imported into the Gambia led to this Acute Kidney Injury (AKI) cluster among children.”

    “Patients with DEG poisoning can experience a range of signs and symptoms, including altered mental status, headache, and gastrointestinal symptoms; however, the most consistent manifestation is AKI, characterized by oliguria (low urine output) or anuria, progressing over 1-3 days to renal failure (indicated by elevated serum creatinine and blood urea nitrogen),” read the report.

    According to the CDC, they were contacted by Gambia’s Ministry of Health (MoH) to assist in characterizing the illness (multiple cases of Acute Kidney Injury and deaths in children), describing the epidemiology, and identifying potential causal factors and their sources in August last year.

    The report also said that in past DEG outbreaks, manufacturers have been suspected of substituting DEG in the place of more expensive, pharmaceutical-grade solvents.

    “Among reports of AKI associated with DEG-contaminated medical products, this is the first in which DEG-contaminated medications were imported into a country, rather than being domestically manufactured,” it said.

    It further said medications for export might be subject to less rigorous regulatory standards than those for domestic use.

    “Simultaneously, low-resource countries might not have the human and financial resources to monitor and test imported drugs,” it stated.

    Union Minister of State for Health Bharati Pravin Pawar in a reply to Lok Sabha on February 3 had said that after testing, the samples of the cough syrups have been declared to be of standard quality.

    The samples were found to be negative for both Diethylene Glycol (DEG) and Ethylene Glycol (EG), Pawar had said in a written reply to a question.

    [ad_2]
    #report #suggests #child #deaths #Gambia #linked #madeinIndia #cough #syrups

    ( With inputs from www.siasat.com )

  • Serum Institute launches 1st made-in-India HPV vaccine for cervical cancer

    Serum Institute launches 1st made-in-India HPV vaccine for cervical cancer

    [ad_1]

    New Delhi: Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Tuesday announced the launch of the first made-in-India Human Papillomavirus (HPV) “CERVAVAC” vaccine, for the prevention of cervical cancer.

    The launch took place in the presence of Home Minister Amit Shah, Adar Poonawalla, and the Director of Government & Regulatory Affairs at Serum Institute of India, Prakash K Singh.

    “On the occasion of India’s National Girl Child Day and Cervical Cancer Awareness Month, @SerumInstIndia is pleased to launch the first made-in-India HPV vaccine by the hands of our Hon’ble Home Minister Shri @AmitShah Ji. @PrakashKsingh7,” tweeted Adar Poonawalla.

    ‘CERVAVAC’ is an outcome of a partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute of India Private Limited for the indigenous development of quadrivalent vaccine through its partnership programme ‘Grand Challenges India’.

    Earlier in December last, Dr NK Arora, chairman of the Covid working group, National Technical Advisory Group on Immunisation (NTAGI) had said that it is expected India to get the HPV vaccine, by April at one-tenth cost.

    Speaking to ANI, Dr Arora said, “There are two or three companies which are in the process (of manufacturing the vaccine in India) but the Serum Institute of India (SII) has already got the regulators’ clearance and the vaccine should be available for our patients by April or May 2023.”

    “The vaccine should be available soon. I don’t know the exact cost yet but am given to understand that the cost of the vaccine will be one-tenth of the internationally-branded vaccine currently available,” he added.

    Dr Arora further informed that almost 80,000 cases of cervical cancer occur in India every year.

    “During the last 24 hours, our country lost 95-100 women due to cervical cancer. India accounts for the bulk of deaths from cervical cancer in the world. Almost 80,000 cases are reportedly worldwide every year. What is important to note here is that cervical cancer is entirely preventable through vaccination. The Human Papilloma Virus or HPV causes cervical cancer and a vaccine is available which can prevent it,” he added.

    He said the Union government will be able to roll out the HPV vaccine as part of its national health programme for girls aged between 9 and 14 years.

    [ad_2]
    #Serum #Institute #launches #1st #madeinIndia #HPV #vaccine #cervical #cancer

    ( With inputs from www.siasat.com )